A Study of Chemotherapy-induced Nausea and Vomiting Involving Different Dosage Regimens of Cisplatin

Objective To compare fractionated doses cisplatin(DDP) with single high-dose cisplatin on reducing Chemotherapy-induced nausea and vomiting(CINV) and improving patients' living function. Methods From October 2011 to June 2012, 101 cases treated by combined chemotherapy with cisplatin were divided into two groups by different ways of DDP treatment, Group A: DDP 75 mg/m², iv drip, d1; Group B: DDP 25 mg/m², iv drip, d1-3. Patients diary recorded episodes of CINV two times during each cycle on day 2 (24 hours after chemotherapy administration) and on day 6. In addition, all patients completed a functional living index-emesis (FLIE) questionnaire, on day 6, each cycle for two circles. Results In acute phase the remission rate of nausea and vomiting were 69.4%, 77.6% in Group A and more decreased than 88.5%, 92.3% in Group B, respectively (P<0.05). In delayed phase the remissions of nausea and vomiting were 32.7%, 55.1% in Group A and higher compared with 34.6%, 71.2% in Group B (P>0.05). Based on the FLIE assessment, the patients of reduced daily function was 46.9% in group A, and similar to 28.7% in Group B （P>0.05）. Conclusion Compared with DDP of single high-dose, DDP of fractionated doses could reduce the prevalence of CINV in acute phase, but in delayed phase. And there is no difference of influence on patients' living function between the two ways.